Scripps Translational Science Institute
Trial Pipeline
The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
NCT06244940
The Long COVID-19 Wearable Device Study
NCT05741112
Research Framework Exploring Sleep Health
NCT05197738
The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study
NCT04336020
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
NCT03277365
POWERMOM, A Healthy Pregnancy Research Community
NCT03085875
Molecular Autopsy Study
NCT02168088
The Healthy Elderly Longevity Cohort
NCT01004133
The Long COVID Treatment Trial
NCT07128082
PRediction Of Glycemic RESponse Study
NCT04881019
Molecular and Morphologic Characterization of Circulating Endothelial Cells
NCT01005485
The Biorepository for Scripps Health
NCT01006239
Scripps Genomics Health Initiative
NCT00808587
The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
NCT00766948
Genomic Investigation of Cardiovascular Diseases
NCT00722748
Scripps Tumorgraft Study
NCT01726699
Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril
NCT01258764
Human Tumor Sequencing Project
NCT01608230
Scripps Polster Breast Care Center Investigational GeneBank
NCT00945464
Genetic Investigation of Solid Tumors Cohort
NCT01005225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
What the Pipeline for Scripps Translational Science Institute Shows
According to the ClinicalTrials.gov registry, Scripps Translational Science Institute is linked to 51 US clinical trials across every stage of research activity. Of those, 39 studies are currently recruiting — about 76% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 10% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Scripps Translational Science Institute reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Scripps Translational Science Institute is Long COVID with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.